Curriculum Vitae – Lucia Biasutto

Birth: November 28th, 1980
E-mail: lucia.biasutto@cnr.it

Current position
02/2012-present: researcher, CNR Neuroscience Institute, Padova

Education and training
01/2011 – 01/2012: Post-doctoral fellow, CNR Neuroscience Institute, Padova.
01/2009 – 12/2010: Post-doctoral fellow, Dept Biomedical Sciences, U. of Padova.
10/2009-04/2010 and 10/2010-11/2010: Centre of Applied Proteomics and Molecular Medicine, George Mason University, Manassas (VA, USA).
01/2006 – 12/2008: Graduate School of Biosciences, cellular biology program, U. of Padova. PhD degree granted on April 06, 2009.
05/2008: Dept. Pharmaceutical Technologies, U. of Innsbruck, Austria.
02/2008: Lab. of Mass Spectrometry, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland.
04/12/2005: Research fellow, U. of Padova.
03/2005: Laurea in Industrial Biotechnology (cum laude), U. of Padova.
07/1999: "Maturità scientifica" (Science-oriented High School), 100/100 cum laude.

Research interests
Dr. Biasutto interests are mainly focused on natural compounds and their utilization in the biomedical field. Research activity includes the development of derivatives to improve their pharmacological exploitation, pharmacokinetics studies, and investigation of the mechanisms of action underlying the activity of both natural compounds and their derivatives.

Bibliometry (updated February 7th, 2025):
Papers in peer-reviewed journals: 64
Other papers (book chapters): 2
Contributions at meetings: >70
Citations: 2381 (Scopus), 2185 (Web of Science)
H index: 30 (Scopus), 29 (Web of Science)

Selected recent publications
- Zoratti M et al. Mitochondrial permeability transition pore: a snapshot of a therapeutic target. Expert Opin Ther Targets. 2024;28:1-3. IF_{2023}: 4.6.
- Parrasia S et al. DA7R: A 7-Letter Zip Code to Target PDAC. Pharmaceutics. 2023;15:1508. IF_{2023}: 5.4.
- Parrasia S et al. An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors.Pharmaceuticals (Basel). 2021;14:129. IF_{2021}: 5.215.
- Peruzzo R et al. Exploiting pyocyanin to treat mitochondrial disease due to respiratory complex III dysfunction. Nat Commun. 2021;12:2103 IF_{2021}: 17.694.
- Szabo I et al. Targeting mitochondrial ion channels for cancer therapy. Redox Biol. 2020:101846. IF_{2021}: 10.787.